Syverson Strege & Co’s Biogen BIIB Stock Holding History

Syverson Strege & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	321
2021 Q3	$0	Buy	+1	New	+$328	﹤0.01%	449

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Syverson Strege & Co's BIIB Position: Q4 2021 in Review

Syverson Strege & Co sold out of Biogen (BIIB) in Q4 2021, closing a stake of 1 share.

Syverson Strege & Co first reported a position in BIIB in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Syverson Strege & Co reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Syverson Strege & Co sold 1 Biogen share in Q4 2021.
Syverson Strege & Co first reported a position in Biogen in Q3 2021 and held it in 1 quarter.
Syverson Strege & Co's Biogen position peaked at $0 in Q3 2021.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Syverson Strege & Co's 13F filing for Q4 2021, filed 19 Jan 2022.